ABSTRACT
Background Immune checkpoint inhibitors (ICIs) are a valuable treatment option for patients with malignant tumors, but only selected patients respond to ICIs. Available biomarkers are of limited use in guiding ICI therapy.
Objective To examine clinicians’ perspective on the use of ICIs and biomarkers for treatment of malignant tumors and to identify unmet needs related to their use.
Methods We conducted in-depth telephone interviews of eight oncologists, and 100 oncologists completed online surveys.
Results Oncologists have a positive attitude toward use of ICIs, and 98% of them prescribe them in all approved indications. Clinicians report that only about half of the patients with solid tumors responded to treatment, overestimated the response rate to ICIs across most types of tumors they treat compared with data in the literature. They ranked the lack of reliability of biomarkers to guide treatment (rating of 4.4 out of 7) as the top challenge with use of ICIs, followed by lack of overall efficacy and toxicity or occurrence of immune-related adverse events. The biomarkers most often used by survey participants were: a comprehensive panel including driver mutations and tumor mutational burden(69% of respondents), programmed cell death ligand-1 (PD-L1) expression (62%), and microsatellite instability (MSI) (56%). Oncologists indicated that they ordered biomarkers for each type of cancer according to their perceived usefulness of each biomarker in predicting the outcomes for ICI therapy, being more likely to use those perceived as useful or very useful.
Conclusion Clinicians indicate that more reliable therapy-response prediction biomarkers would have a great impact on treatment decisions for patients with solid tumors, reducing unnecessary treatments, side effects, and health care expenditures.
Competing Interest Statement
Authors affiliated with Olson Research Group and Ascenian Consulting and Market Research received compensation as 3rd party vendors for their contribution; authors affiliated with InterVenn are full-time employees of the company.,
Funding Statement
This study was funded by InterVenn
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We conducted an anonymous online survey. The survey was conducted in accordance with the principles and guidelines established by the Office for Human Research Protections and the Insights Association Code of Standards and Ethics. The study protocol was reviewed and approved by the Western Institutional Review Board-Copernicus Group (WCG IRB, Pyallup, WA 98374, USA) under protocol number #1-1531933-1.After reviewing information about the purpose and nature of the survey, respondents selected a yes/no option indicating consent to participate in the study prior to entering the screening portion of the survey. If they consented, they continued to the survey questions. Respondents could discontinue the survey at any time.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
ABBREVIATIONS
- AUC
- area under the receiver operating characteristic curve
- CTLA-4
- cytotoxic T-lymphocyte-associated antigen-4
- GI
- gastrointestinal
- ICI
- immune-checkpoint inhibitor
- KOL
- key opinion leader
- MSI
- microsatellite instability
- NSCLC
- non-small-cell lung cancer
- PD-1
- programmed cell death protein 1
- PD-L1
- programmed cell death ligand-1
- RCC
- renal cell carcinoma
- TMB
- tumor mutational burden
- NCCN
- National Comprehensive Care Network
- NCI
- National Cancer Institute
- SD
- standard deviation.
